Global Precision Medicine Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Precision Medicine Market Size

• The global precision medicine market size was valued at USD 9.29 billion in 2024 and is expected to reach USD 24 billion by 2032, at a CAGR of 12.60% during the forecast period
• This growth is driven by factors such as advancements in genomic technologies, rising prevalence of chronic diseases, and increasing integration of artificial intelligence in personalized healthcare solutions

Precision Medicine Market Analysis

• Precision medicine is a transformative approach to healthcare that tailors medical treatment to individual characteristics such as genetics, environment, and lifestyle, enhancing treatment efficacy and reducing adverse effects. It plays a pivotal role in areas like oncology, cardiology, and rare genetic disorders
• The demand for precision medicine is being driven by the rising prevalence of chronic diseases, the growing availability of genomic data, and technological advancements in diagnostic tools and data analytics
• North America is expected to dominate the global precision medicine market with largest market share of 53.63%, due to strong R&D infrastructure, significant government and private investments, and early adoption of advanced healthcare technologies
• Asia-Pacific is expected to be the fastest growing region in the precision medicine market during the forecast period due to increasing healthcare awareness, supportive government initiatives, and expanding genomic research activities
• Therapeutics segment is expected to dominate the market with a largest market share of approximately 58.7%, due to the increasing prevalence of chronic diseases and the rising demand for personalized treatment options. Advancements in genomics, pharmacogenomics, and biotechnology have enabled the development of targeted therapies that are more effective and have fewer side effects compared to traditional treatments

Report Scope and Precision Medicine Market Segmentation 

Precision Medicine Market Trends

“Integration of Artificial Intelligence and Genomic Data in Precision Medicine”

• One prominent trend in the global precision medicine market is the increasing integration of artificial intelligence (AI) and machine learning with genomic data analysis to accelerate drug discovery and personalize treatment strategies
• These technologies enable rapid interpretation of complex datasets, improving the accuracy of diagnostics and enhancing the prediction of treatment responses across various diseases 
  • For instance, AI-driven platforms are now being used to analyze genomic profiles and identify potential biomarkers, significantly reducing the time required for clinical decision-making and improving therapeutic outcomes
• This trend is revolutionizing the precision medicine landscape by enabling more efficient, data-driven approaches to healthcare, fostering innovation in targeted therapies, and expanding the potential for truly personalized patient care

Precision Medicine Market Dynamics

Driver

“Rising Prevalence of Chronic and Genetic Diseases”

• The growing burden of chronic and genetic diseases such as cancer, cardiovascular disorders, diabetes, and rare inherited conditions is a major driver of the global precision medicine market
• These conditions often require individualized treatment approaches, prompting the adoption of precision medicine to improve patient outcomes and minimize adverse drug reactions
• With the global population aging and lifestyle-related diseases on the rise, healthcare systems are increasingly turning to precision medicine for more effective and targeted therapies

For instance,

• According to the World Health Organization (2023), noncommunicable diseases account for over 70% of all global deaths annually, highlighting the urgent need for tailored medical interventions based on genetic, environmental, and lifestyle factors 
• As a result, the rising incidence of complex, chronic conditions is significantly accelerating the adoption of precision medicine, reinforcing its role as a key solution in modern healthcare delivery

Opportunity

“Rising Adoption of Companion Diagnostics to Enhance Treatment Precision”

• The increasing use of companion diagnostics presents a major opportunity in the precision medicine market by enabling more accurate selection of therapies based on individual genetic profiles
• Companion diagnostics help identify patients who are most likely to benefit from a specific drug, ensuring higher treatment efficacy and minimizing adverse reactions
• This approach supports regulatory approvals of targeted therapies and improves clinical outcomes, especially in oncology, immunology, and rare genetic disorders

For instance,

• According to the U.S. FDA, the number of approved drugs with associated companion diagnostics has significantly increased over the past decade, particularly in cancer treatment, where genetic testing guides therapeutic decisions 
• The growing reliance on companion diagnostics is expected to drive innovation and expansion in the precision medicine market, as pharmaceutical companies and diagnostic firms collaborate to develop integrated, patient-specific solutions

Restraint/Challenge

“High Costs and Limited Access to Advanced Technologies”

• The high cost of precision medicine technologies, including advanced genomic sequencing, biomarker testing, and personalized therapies, poses a significant challenge, especially in low- and middle-income regions
• These technologies, which are crucial for tailoring treatments to individual patients, often come with substantial upfront costs, limiting accessibility for healthcare systems and patients with limited budgets
• Smaller healthcare facilities and research institutions may struggle to adopt these advanced solutions, resulting in unequal access to cutting-edge precision medicine treatments

For instance,

• In According to a report by the World Health Organization (WHO) in 2023, the high costs of next-generation sequencing and molecular diagnostics are among the key barriers preventing widespread implementation of precision medicine, particularly in developing nations 
• As a result, the financial constraints and unequal distribution of resources limit the scalability and affordability of precision medicine, ultimately hindering its global market expansion and adoption

Precision Medicine Market Scope

The market is segmented on the basis of application, technologies, indication, drugs, route of administration, and end users.

In 2025, the therapeutics is projected to dominate the market with a largest share in application segment

The therapeutics segment is expected to dominate the precision medicine market with the largest share of approximately 58.7%, due to the increasing prevalence of chronic diseases and the rising demand for personalized treatment options. Advancements in genomics, pharmacogenomics, and biotechnology have enabled the development of targeted therapies that are more effective and have fewer side effects compared to traditional treatments

The hospitals is expected to account for the largest share during the forecast period in end users segment

In 2025, the hospitals segment is expected to dominate the market with the largest market share of 60.01%, due to their comprehensive infrastructure and access to diverse patient populations. Moreover, hospitals often participate in clinical trials and research, ensuring cutting-edge treatments are available. Their ability to rapidly adapt to new technologies and incorporate patient feedback further enhances the efficacy of precision medicine

Precision Medicine Market Regional Analysis

“North America Holds the Largest Share in the Precision Medicine Market”

• North America dominates the global precision medicine market with largest market share of 53.63%, driven by advanced healthcare infrastructure, a high adoption rate of cutting-edge medical technologies, and the strong presence of key pharmaceutical and biotechnology companies
• The U.S. holds a significant share of approximately 48.9%, due to the increasing demand for personalized therapies, rising prevalence of chronic diseases such as cancer and diabetes, and continuous advancements in genomics and molecular biology
• The availability of well-established reimbursement policies, growing investments in research & development, and the presence of world-renowned medical institutions further strengthen the market
• In addition, increasing awareness of the benefits of precision medicine and the growing trend of personalized treatments among patients contribute to the region's market dominance

“Asia-Pacific is Projected to Register the Highest CAGR in the Precision Medicine Market”

• The Asia-Pacific region is expected to witness the highest growth rate in the precision medicine market, driven by rapid advancements in healthcare infrastructure, growing awareness about personalized medicine, and increasing investments in biotechnology
• Countries such as China, India, and Japan are emerging as key markets due to the growing aging population, rising incidences of genetic disorders, and increasing healthcare expenditure
• Japan, with its advanced medical technology, strong research ecosystem, and growing number of biotech startups, remains a crucial market for precision medicine, particularly in oncology and genetic testing
• China and India, with their large populations and rising healthcare demands, are witnessing increased government and private sector investments in genomics, biomarker research, and healthcare technologies, which further contribute to market growth

Precision Medicine Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Moderna, Inc. (U.S.)
• Personalis, Inc. (U.S.)
• CureVac SE (Germany)
• Celldex Therapeutics (U.S.)
• BioNTech SE (Germany)
• Agenus Inc. (U.S.)
• Immatics N.V. (Germany)
• Gritstone bio (U.S.)
• ImmunityBio, Inc. (U.S.)
• BIOMÉRIEUX (France)
• Bayer AG (Germany)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Illumina, Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• QIAGEN (Germany)
• Abbott Laboratories (U.S.)
• Koninklijke Philips N.V. (Netherlands)

Latest Developments in Global Precision Medicine Market

• In May 2024, Atara Biotherapeutics submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (tab-cel) as a proposed standalone treatment for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) in adults and children aged 2 years and older, who have previously received at least one therapy. The submission of this BLA underscores the increasing role of precision medicine in targeting specific, hard-to-treat diseases
• In May 2024, Dragonfly Therapeutics, Inc., a biotechnology company focused on developing innovative immunotherapies, announced a clinical collaboration with Merck (known as MSD outside the U.S. and Canada). The integration of targeted therapies, such as DF9001 and KEYTRUDA, highlights the growing importance of precision medicine in oncology, offering highly personalized treatment approaches that are tailored to the genetic and molecular characteristics of individual tumors
• In January 2024, BIOS Health announced a strategic partnership with the Kern Venture Group to establish a precision medicine hub in Bakersfield, California. This collaboration aims to foster innovation in personalized healthcare by advancing research and development efforts in precision medicine, ultimately improving patient outcomes in the region. This partnership aligns with the global trend of expanding precision medicine initiatives, which are increasingly recognized for their ability to deliver tailored treatments based on individual genetic profiles and specific disease characteristics
• In November 2023, Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration (FDA) approval of Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor (TKI), for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The approval of Augtyro represents a significant milestone in the field of precision medicine, as it highlights the increasing importance of targeted therapies based on specific genetic biomarkers, such as ROS1 mutations
• In February 2022, Oncodesign and SEngine Precision Medicine Inc. entered into a research collaboration agreement aimed at developing advanced, personalized cancer therapies for patients suffering from aggressive and untreatable cancers. The collaboration underscores the growing importance of precision medicine in oncology, emphasizing the shift toward personalized, targeted therapies

SKU-9750